Dr Lal PathLabs Q1 FY27: Net Profit Jumps 29%, Revenue Rises 19%; ₹5 Interim Dividend Announced

Diagnostic services provider Dr Lal PathLabs Ltd. reported a strong financial performance in the first quarter of FY27 with strong double-digit growth in revenue and profitability. The company also rewarded its shareholders with an interim dividend of ₹5 per equity share.

Revenue and profit growth to a great extent

In the quarter ended June 2026, consolidated net profit increased by 28.8% year-on-year (YoY) to ₹170 crore compared to ₹132 crore in the previous quarter of the year.

Revenue from operations also grew strongly by 19.1% YoY to ₹798 crore, up from ₹670 crore in Q1 FY26. The strong top-line growth is also a testimony to continued demand for diagnostic testing services and good business performance across its network.

EBITDA and Margins Improve

At the operating level, EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) increased 28.7% to ₹248 crore, compared to ₹192 crore in the same quarter last year.

The company’s operational efficiency also improved, with the EBITDA margin increasing to 31% from 28.7% in Q1 FY26. Margins that are higher, more efficient, with better cost control and operating leverage.

Q1 FY27 Financial Highlights

Metric Q1 FY27 Q1 FY26 Growth. Gross revenue was ₹798 crore, net profit was ₹170 crore, EBITDA was ₹248 crore, and EBITDA margin was 28.7%, an improvement. ₹5 interim dividend

Apart from the quarterly earnings, the Board of Directors voted to pay an interim dividend of ₹5 per equity share for the financial year 2026-27.

Important Dividend Dates

Investor cash flow (operating net worth) was the same as on the previous day, but the balance of the interest was still higher as of the current date.

Only shareholders whose names appear in the company's records as of the record date will be eligible to receive the interim dividend.

Share Price Performance

Following the earnings announcement, Dr Lal PathLabs shares were up a little bit.

At 1:55 p.m., the stock was up 0.31% to ₹1,691.90 per share, outperforming the market. At the same time, the BSE Sensex was down 0.45%.

Outlook

The good revenue growth, improved profitability and expanding operating margins indicate the resilience and resilience of India’s diagnostics industry. Further expansion of test capacity, expanding laboratory infrastructure and network expansion across the country should drive future growth.

As we move forward, market participants are going to continue to monitor the company’s patient volumes, preventive healthcare demand and expansion plans in the coming quarters to see how long it can grow.